International Survey from Biogen Identifies Opportunities for Improving MS Treatment Satisfaction
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Baird Remains Buyers of Biogen (BIIB) Despite Kyle Bass Tecfidera Challenge
April 22, 2015 3:50 PM EDTBaird analyst Christopher Raymond weighed in on Biogen (NASDAQ: BIIB) this afternoon following news hedge fund manager Kyle Bass has filed an IPR against a Tecfidera patent.
The analyst said the challenge does not come as a surprise and they predicted this in February after... More
Kyle Bass files challenge to Biogen (BIIB) patent on Tecfidera - Bloomberg
April 22, 2015 11:13 AM EDTKyle Bass files challenge to Biogen (NASDAQ: BIIB) patent on Tecfidera - Bloomberg
... More